<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03659760</url>
  </required_header>
  <id_info>
    <org_study_id>EmineMelatonin</org_study_id>
    <nct_id>NCT03659760</nct_id>
  </id_info>
  <brief_title>: Association of Melatonin Levels and Light and Noise Isolation in ICU</brief_title>
  <official_title>Does Light and Noise Isolation Change the Melatonin Levels and Inflammatory Response After Cranial Surgery in an Intensive Care Unit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diskapi Yildirim Beyazit Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diskapi Yildirim Beyazit Education and Research Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Melatonin is secreted from the epiphyseal gland with a circadian rhythm and is known to be
      anti-inflammatory.

      In this study, it is planned to investigate the effect of sleep disruptions on melatonin
      levels and inflammation parameters in intensive care patients underwent transcranial surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Glasgow coma scale (GKS) &gt;14, American Society of Anesthesiologist (ASA) I-III,
      intensive care patients underwent transcranial surgery will be included

      Patients will be randomly allocated by a computer generated random numbers list into two
      groups.

      Patients with sleep disruptions (Group I) (exposed to ambient light and noise) and Patients
      without sleep disruptions (Group II) (eyes closed with patch and ear plugged; between
      24:00-06:00)

      Melatonin levels will be measured by urine 6-sulfatoxymelatonin (a-MT6) levels, which is a
      product of melatonin degradation at 07:00 am preoperative and postoperative day 1 and day 3.

      Plasma Interleukin-1 (IL-1), Interleukin- 6 (IL-6),C-reactive protein (CRP) levels will be
      measured at 07:00 am preoperative and postoperative day 1and day 3.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective randomize</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Melatonin level</measure>
    <time_frame>At preoperative 07:00 am</time_frame>
    <description>Melatonin will be measured urine 6-sulphatoxymelatonin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Melatonin level</measure>
    <time_frame>07:00 am postoprative day 1</time_frame>
    <description>Melatonin will be measured urine 6-sulphatoxymelatonin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Melatonin level</measure>
    <time_frame>07:00 am postoprative day 3</time_frame>
    <description>Melatonin will be measured urine 6-sulphatoxymelatonin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>IL-1,IL-6,CRP</measure>
    <time_frame>: at 7 o'clock in the morning preoperative day, 7 in the morning on the first postoperative day and 7 in the morning on the third postoperative day hour</time_frame>
    <description>serum</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cranial Nerve Diseases</condition>
  <arm_group>
    <arm_group_label>Group Isolated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group Isolated (Group II) (eyes closed with patch and ear plugged; between 24:00-06:00)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Disrupted</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group Disrupted (Group I) (exposed to ambient light and noise)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Group Isolated</intervention_name>
    <description>Eyes closed with patch and ears plugged between 24:00-06:00</description>
    <arm_group_label>Group Isolated</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  ASA 1-3

          -  Glasgow Coma Scale(GCS) &gt;14

        Exclusion Criteria:

          -  Glasgow Coma Scale(GCS) &lt;14

          -  Patients who do not understand the questions, not awake

          -  Patient who treated with hormones

          -  Patient with infection or inflammatory disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emine Arık</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dr</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emine Arık</last_name>
    <phone>+905333471530</phone>
    <email>emineincearik@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emine Arık</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universty of Health Sciences, Dıskapı Yıldırım Beyazıt Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emine Arık</last_name>
      <phone>+90 533 3471530</phone>
      <email>emineincearik@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Grima NA, Rajaratnam SMW, Mansfield D, Sletten TL, Spitz G, Ponsford JL. Efficacy of melatonin for sleep disturbance following traumatic brain injury: a randomised controlled trial. BMC Med. 2018 Jan 19;16(1):8. doi: 10.1186/s12916-017-0995-1.</citation>
    <PMID>29347988</PMID>
  </reference>
  <reference>
    <citation>Yaşar NF, Badak B, Canik A, Baş SŞ, Uslu S, Öner S, Ateş E. Effects of Sleep Quality on Melatonin Levels and Inflammatory Response after Major Abdominal Surgery in an Intensive Care Unit. Molecules. 2017 Sep 12;22(9). pii: E1537. doi: 10.3390/molecules22091537.</citation>
    <PMID>28895895</PMID>
  </reference>
  <reference>
    <citation>Osier N, McGreevy E, Pham L, Puccio A, Ren D, Conley YP, Alexander S, Dixon CE. Melatonin as a Therapy for Traumatic Brain Injury: A Review of Published Evidence. Int J Mol Sci. 2018 May 22;19(5). pii: E1539. doi: 10.3390/ijms19051539. Review.</citation>
    <PMID>29786658</PMID>
  </reference>
  <reference>
    <citation>Kurdi MS, Patel T. The role of melatonin in anaesthesia and critical care. Indian J Anaesth. 2013 Mar;57(2):137-44. doi: 10.4103/0019-5049.111837.</citation>
    <PMID>23825812</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 31, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>October 5, 2018</last_update_submitted>
  <last_update_submitted_qc>October 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diskapi Yildirim Beyazit Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>Emine Arik</investigator_full_name>
    <investigator_title>Specialist in Anesthesia</investigator_title>
  </responsible_party>
  <keyword>Melatonin</keyword>
  <keyword>Interleukin</keyword>
  <keyword>Transcranial</keyword>
  <keyword>Surgery</keyword>
  <keyword>Intensive care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cranial Nerve Diseases</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

